Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Neoplasma Vol.64, No.4, p.605-610, 2017 |
||
Title: Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed | ||
Author: O. Fiala, P. Hosek, M. Pesek, J. Finek, J. Racek, T. Buchler, A. Poprach, K. Hejduk, R. Chloupkova, O. Sorejs, M. Ecksteinova, M. Vitovec, K. Cizkova, R. Kucera, O. Topolcan | ||
Abstract: Pemetrexed is an intravenously administered antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC). It has been previously demonstrated that the superiority of pemetrexed is limited to patients with non-squamous histology. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of baseline serum levels of C-reactive protein (CRP) with outcomes in a large cohort of patients with non-squamous NSCLC treated with pemetrexed. Clinical data of 325 patients were analysed. Serum samples were collected within one week before the initiation of treatment. The median progression-free (PFS) and overall survival (OS) for patients with high CRP was 2.1 and 9.5 compared to 4.2 and 20.5 months for those with normal CRP (p=0.002 and p<0.001, respectively). The multivariable Cox proportional hazards model revealed that serum CRP (HR=1.46, p=0.002) was significantly associated with PFS and also with OS (HR=1.95, p<0.001). In conclusion, the study results suggest that pretreatment serum CRP is associated with poor outcome of non-squamous NSCLC patients treated with pemetrexed. |
||
Keywords: C-reactive protein, lung cancer, NSCLC, chemotherapy, pemetrexed, prognosis | ||
Published online: 11-Jul-2017 | ||
Year: 2017, Volume: 64, Issue: 4 | Page From: 605, Page To: 610 | |
doi:10.4149/neo_2017_416 |
||
|
download file |
|